title: Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma.
abstract: Patients with end-stage renal disease are exposed to increased oxidative stress and impairment of antioxidant mechanisms. We focused on dialysis renal cell carcinoma (RCC), including epithelial hyperplasia in acquired cystic disease of the kidney (ACDK). We attempted to obtain insight into the carcinogenesis and tumor progression in terms of cellular defense mechanisms associated with oxidative stress by investigating the expression of antioxidant proteins by immunohistochemistry. We evaluated retrospectively 43 cases of dialysis RCC and, as a control group, 49 cases of sporadic RCC. Peroxiredoxin (Prx) 1, 3, 4, 5, and 6 expression in dialysis RCC was positively correlated with the duration of dialysis. In epithelial hyperplasia, in 17 cases of acquired cystic disease of the kidney, Prxs and thioredoxin were highly expressed. Moreover, in dialysis RCC, Prx 3, 4, and 5 immunoreactivity and nuclear expression of Y-box-binding protein-1 were higher than in sporadic RCC. In dialysis RCC, Prx 3, 4, and 5 immunoreactivity positively correlated with the Fuhrman nuclear grade. These data suggest that oxidative stress during dialysis enhances antioxidant activity, with an inhibiting effect on carcinogenesis. Once cancer has developed, antioxidant activity might have a stimulating effect on the progression of dialysis RCC.
authors.affiliation: Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan.
authors.forename: Fumiyoshi
authors.initials: F
authors.lastname: Fushimi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Taguchi
authors.forename: Hiroto
authors.initials: H
authors.lastname: Izumi
authors.forename: Kimitoshi
authors.initials: K
authors.lastname: Kohno
authors.forename: Michihiko
authors.initials: M
authors.lastname: Kuwano
authors.forename: Mayumi
authors.initials: M
authors.lastname: Ono
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nakashima
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Takesue
authors.forename: Seiji
authors.initials: S
authors.lastname: Naito
authors.forename: Yoshinao
authors.initials: Y
authors.lastname: Oda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology; D054464:Peroxiredoxins / Q000032:analysis / Q000096:biosynthesis*; D006435:Renal Dialysis / Q000009:adverse effects*; D012189:Retrospective Studies; D013879:Thioredoxins / Q000032:analysis / Q000096:biosynthesis*; D051840:Y-Box-Binding Protein 1 / Q000032:analysis / Q000096:biosynthesis*
chemical_list: D051840:Y-Box-Binding Protein 1; D013879:Thioredoxins; D054464:Peroxiredoxins
references.citation: Semin Dial. 2011 Jan-Feb;24(1):56-64
references.pmid: 21299632
references.citation: Cancer Sci. 2008 Oct;99(10):1950-9
references.pmid: 19016754
references.citation: Cancer Lett. 2009 Dec 28;286(2):154-60
references.pmid: 19500902
references.citation: Eur Radiol. 2000;10(11):1716-21
references.pmid: 11097395
references.citation: Genes Chromosomes Cancer. 2002 Dec;35(4):359-64
references.pmid: 12378530
references.citation: Lung. 2008 Mar-Apr;186(2):103-14
references.pmid: 18219526
references.citation: Biochemistry. 2002 Oct 22;41(42):12739-44
references.pmid: 12379116
references.citation: Eur J Biochem. 2000 Oct;267(20):6102-9
references.pmid: 11012661
references.citation: J Pathol. 2007 Jun;212(2):218-26
references.pmid: 17451187
references.citation: Exp Cell Res. 2006 Sep 10;312(15):2806-15
references.pmid: 16781710
references.citation: Cancer Res. 2005 Jul 1;65(13):5628-37
references.pmid: 15994935
references.citation: Oncogene. 2007 Apr 26;26(19):2736-46
references.pmid: 17072343
references.citation: Cancer Res. 1996 Sep 15;56(18):4224-8
references.pmid: 8797596
references.citation: Cell Res. 2011 Jan;21(1):103-15
references.pmid: 21187859
references.citation: Biol Chem. 2002 Mar-Apr;383(3-4):347-64
references.pmid: 12033427
references.citation: Cancer Sci. 2008 Apr;99(4):726-32
references.pmid: 18377424
references.citation: Trends Pharmacol Sci. 2005 Aug;26(8):398-404
references.pmid: 15990177
references.citation: Hum Pathol. 2002 Jul;33(7):761-5
references.pmid: 12196929
references.citation: Hum Pathol. 2010 Sep;41(9):1345-9
references.pmid: 20646738
references.citation: Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7004-9
references.pmid: 21487000
references.citation: Clin Cancer Res. 2003 Aug 15;9(9):3418-24
references.pmid: 12960131
references.citation: BJU Int. 2010 Mar;105(5):620-7
references.pmid: 19747356
references.citation: Am J Surg Pathol. 2006 Feb;30(2):141-53
references.pmid: 16434887
references.citation: J Exp Clin Cancer Res. 2009 Jun 30;28:93
references.pmid: 19566940
references.citation: Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):868-78
references.pmid: 20732753
references.citation: Urology. 1999 Jan;53(1):44-9
references.pmid: 9886586
references.citation: Hum Pathol. 2009 Jul;40(7):965-74
references.pmid: 19269675
references.citation: Am J Surg Pathol. 1982 Oct;6(7):655-63
references.pmid: 7180965
references.citation: Oncogene. 2010 Jan 21;29(3):403-10
references.pmid: 19838214
references.citation: Mod Pathol. 2006 Jun;19(6):780-7
references.pmid: 16575398